Literature DB >> 12020171

Effective communication of drug safety information to patients and the public: a new look.

Eleanor M Vogt1.   

Abstract

Recent parallel developments in the fields of medicine and the social sciences are providing us with new insights and resources that have the potential for improving the effectiveness of drug safety communication and decision-making. These developments include medicine's new look at patient safety with its emphasis on complex adaptive systems, education's new appreciation for learning as an internal change process and risk communication's evolving recognition that relevant knowledge may not be the exclusive property of 'experts'. Eight principles are drawn from this analysis: there cannot be a safer drug until there is a safer system;all stakeholders are equal partners and have an equal voice in all deliberations;paternalism must be eliminated;the expertise for determining acceptable benefit and risk is dispersed throughout society;patients and all stakeholders serve as both teachers and learners;all stakeholders are involved in the identification of their learning needs, processes and evaluation of outcomes;in a complex adaptive system all individual actions are interconnected and;patients must be involved in the continuous feedback and redesign of the evolving drug safety information system. The conclusion is that we are not asking the right questions; 'what information should we communicate?' and 'how do we communicate more effectively?' should be reframed to ask 'how do we provide an equal voice for patients with the other stakeholders in the determination and communication of benefit-risk information?' Some patients are not waiting. The International Alliance of Patient Organizations (IAPO), the Database of Individual Patient Experience (Dipex) and the Self-Help Group Clearinghouse are examples of international patient driven efforts to actively participate in their own care. The author suggests that the emerging discipline of inter-active management can contribute methodologies for creating citizenship models to generate the collective wisdom and translate it into action. A future research agenda calls for creating new models of public accountability that support these evolving systems of engaging the entire community in benefit-risk determination, communication and management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020171     DOI: 10.2165/00002018-200225050-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  8 in total

1.  Promotion of prescription drugs to consumers.

Authors:  Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

2.  Risk perception and communication unplugged: twenty years of process.

Authors:  B Fischhoff
Journal:  Risk Anal       Date:  1995-04       Impact factor: 4.000

3.  "New Look" reflects changing style of patient safety enhancement.

Authors:  D F Phillips
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

Review 4.  The challenge of effectively communicating risk-benefit information.

Authors:  I R Edwards; B Hugman
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

5.  Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

Authors:  R Edwards; B E Wiholm; C Martinez
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

6.  Drug-related morbidity and mortality. A cost-of-illness model.

Authors:  J A Johnson; J L Bootman
Journal:  Arch Intern Med       Date:  1995-10-09

7.  Drug-related morbidity and mortality: updating the cost-of-illness model.

Authors:  F R Ernst; A J Grizzle
Journal:  J Am Pharm Assoc (Wash)       Date:  2001 Mar-Apr

8.  Increased fetal loss in women with heritable thrombophilia.

Authors:  F E Preston; F R Rosendaal; I D Walker; E Briët; E Berntorp; J Conard; J Fontcuberta; M Makris; G Mariani; W Noteboom; I Pabinger; C Legnani; I Scharrer; S Schulman; F J van der Meer
Journal:  Lancet       Date:  1996-10-05       Impact factor: 79.321

  8 in total
  4 in total

Review 1.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Survey of medication knowledge and behaviors among college students in Taiwan.

Authors:  Fei-Yuan Hsiao; Jen-Ai Lee; Weng-Foung Huang; Shih-Ming Chen; Hsiang-Yin Chen
Journal:  Am J Pharm Educ       Date:  2006-04-15       Impact factor: 2.047

Review 3.  Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.

Authors:  Monica van Hoof; Katherine Chinchilla; Linda Härmark; Cristiano Matos; Pedro Inácio; Florence van Hunsel
Journal:  Drug Saf       Date:  2022-08-25       Impact factor: 5.228

4.  Problem-based training improves recognition of patient hazards by advanced medical students during chart review: a randomized controlled crossover study.

Authors:  Friederike Holderried; Daniel Heine; Robert Wagner; Moritz Mahling; Yelena Fenik; Anne Herrmann-Werner; Reimer Riessen; Peter Weyrich; Stephan Zipfel; Nora Celebi
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.